



Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.

This document authorises the supply of Fusidic Acid Cream 2% by registered pharmacists to patients aged over 2 years old who meet the criteria for inclusion under the terms of the document

The Registered pharmacists seeking to supply Fusidic Acid Cream 2% must ensure that all patients have been screened and meet the criteria before supply takes place

The purpose of this Patient Group Direction is to allow management of Minor Staphylococcal Skin Infections (Impetigo) in NHS Border by registered pharmacists

PGD previously approved: New PGD

This direction was authorised on: July 2017

The direction will be reviewed by: July 2019

Author of PGD: Adrian Mackenzie, Lead Pharmacist, Community Pharmacy

Clinician(S) responsible for Training and Audit: Lead Pharmacist, Community Pharmacy

Specialist clinical review by: Anne Duguid, Antimicrobial Pharmacist



Patient Group Direction for the supply and/or administration Fusidic Acid Cream 2% without a prescription for a named individual by registered pharmacists contracted to or employed by NHS Borders.

1. This Patient Group Direction relates to the following specific preparation:

Name of medicine, strength, formulation	Fusidic Acid Cream 2%
Legal status	POM
Storage	No special precautions
Dose	Apply to lesions three to four times daily for seven days
Route/method	Topical application
Frequency	Apply to lesions three to four times daily for seven days. Maximum of one supply in 3 months.
Total dose Quantity (Maximum/Minimum)	15g tube
Advice to Patients	<ul style="list-style-type: none"> ▪ Wash hands before and after applying cream ▪ Where possible remove scabs by bathing in warm water before applying the cream ▪ Impetigo is very infectious, to prevent it spreading ensure patients use own flannels and towels and these should be washed in a hot wash after use. ▪ Do not scratch or pick spots ▪ Suggest applying cream three times a day on school days and four times daily at other times. ▪ Inform school/nursery of the condition ▪ Do not share the cream with anyone else ▪ Advise to seek further advice if condition worsens or symptoms persist

	<ul style="list-style-type: none"> Manufacturers Patient Information Leaflet should be offered.
Relevant Warnings	<ul style="list-style-type: none"> Side effects with this product are rare, however hypersensitivity reactions may occur. Fusidic acid can be used during pregnancy and breastfeeding. If breastfeeding it is recommended to avoid applying topical Fusidic acid on the breast. Advise to contact nurse/GP if side effects occur. For a full list of side effects-refer to the marketing authorisation holder's Summary of Product Characteristics (SPC). This can be accessed on https://www.medicines.org.uk/emc/medicine/2374 If a serious adverse reaction is suspected please report to the Commission on Human Medicines (CHM) via the Yellow Card Scheme http://yellowcard.mhra.gov.uk/
Follow up Arrangements	If the skin infection spreads or there is no improvement after 5 days, seek medical advice from GP.

2. Clinical condition:

Clinical Condition to be treated	Minor staphylococcal infection of skin (Impetigo)
Criteria for inclusion	<ul style="list-style-type: none"> Patient is over 2 years of age. Minor skin infection limited to a few lesions in one area of the body. The rash consists of vesicles that weep and then dry to form yellow-brown crusts. Must obtain parental/guardian consent for treating a child under 16 years of age. Patient must be present at consultation.
Criteria for exclusion	<ul style="list-style-type: none"> Multiple site skin infection. Previous history of infections resistant to Fusidic acid Children under 2 years of age. Had impetigo within the last 3 months. Known hypersensitivity to any component of the medicine.

	<ul style="list-style-type: none"> ▪ Patient refuses treatment. ▪ Presenting with any underlying skin condition on the same area of the body as impetigo. ▪ Concerns regarding patient compliance with topical medication.
Action if excluded	<ul style="list-style-type: none"> ▪ Refer to authorised prescriber; GP or BECS, Unscheduled Care NHS 24 ▪ Document in pharmacy medication record (PMR) or patient care record (PCR) ▪ Inform GP of decision to exclude and action taken (referral made), the patient medical record can be updated accordingly
Action if declines	<ul style="list-style-type: none"> ▪ Refer to authorised prescriber ▪ Document refusal in PMR or PCR
Interactions with other medicaments and other forms of interaction	Interactions are minimal, systemic absorption of topical Fusidic acid is negligible. See BNF for latest information

3. Documentation/Record keeping.

a) The following records should be kept (either paper or computer based)-

The GP practice, clinic, hospital, and ward or department
The patient name and CHI number
The medicine name, dose, route, time of dose(s), and where appropriate, start date, number of doses and or period of time, for which the medicine is to be supplied or administered
Drug batch number and expiry
The signature and printed name of the healthcare professional who supplied or administered the medicine
The patient group direction title and/or number
Whether patient met the inclusion criteria and whether the exclusion criteria were assessed

b) Preparation, audit trail, data collection and reconciliation-

Stock balances should be reconcilable with Receipts, Administration, Records and Disposals on a patient by patient basis.

c) Storage-

No special precautions

4. Professional Responsibility.





- All Health Professionals will ensure he/she has the relevant training and is competent in all aspects of medication, including contra-indications and the recognition and treatment of adverse effects.
- He/she will attend training updates as appropriate.
- For those involved in immunization, regular anaphylaxis updates are mandatory.
- Nurses will have due regard for the NMC Professional standards of practice and behaviour for nurses and midwives (The Code 2015) and NMC Standards for Medicines Management (2008)
- Pharmacists must have undertaken appropriate training as deemed necessary by NHS Borders. At the time of PGD approval this is the NES Pharmacy First training Pack.


5. References

- ❖ British National Formulary (BNF) current edition
<https://www.medicinescomplete.com/mc/>
- ❖ Borders Joint Formulary (BJF)
http://intranet/new_intranet/microsites/index.asp?siteid=65&uid=1
- ❖ SPC <https://www.medicines.org.uk/emc/medicine/2374>
- ❖ PGD Adapted from NHS Lothian Patient group direction for Fusidic Acid 2% for the treatment of minor staphylococcal infections (Impetigo)

**Patient Group Direction for the supply and/or administration of Fusidic Acid
2% cream by registered pharmacists employed by or contracted to NHS
Borders**

This Patient Group Direction is approved for use by the under-signed :

Job Title	Name	Signed	Date
Senior Doctor/Dentist for relevant clinical area	Dr Cliff Sharp		9/8/17
NHS Borders Director of Pharmacy	Alison Wilson		8/8/17
NHS Borders Senior Health Professional for Clinical Area	Claire Pearce		8/8/17
NHS Borders Consultant Microbiologist	Edward James		29.8.17

PGD AUTHORISED ON 29/8/17
 Signed by ADTC CHAIRPERSON: 
 Name: Alison Wilson

**The Health Professionals named below, based at
 (*Clinic OR GP Employer Name*)
 are authorised to provide this medication under this Patient Group Direction
 and agree to provide this medication in accordance with this Patient
 Group Direction**

Name of Health Professional	Job Title	Signed	Date